Professor Wang Yongjun is currently the President of Beijing Tiantan Hospital affiliated to Capital Medical University, the deputy Director of the China National Clinical Research Center for Neurological Diseases and Director of the National Center for Healthcare Quality Management in Neurological Diseases. He is also the Chairman of Neurology Branch of Chinese Medical Association, Executive Vice President of Chinese Stroke Association, Vice President of Neurology branch of Chinese Medical Doctor Association, Chairman of Neurology Specialty Committee of Medical Education after Graduation of Chinese Medical Doctor Association. Professor Wang pioneered the CHANCE research for the treatment of high-risk non-disabling cerebrovascular disease, which has been recommended to the world by the US Guidelines for the Management of Acute Ischemic Cerebrovascular Disease (2019 Update) as the highest level of evidence, and it had become the highest international standard for the treatment in this area. He presided over the establishment of the first standardized stroke unit for cerebrovascular disease wards in China, and formulated two national health industry standards as well as five industry guidelines, and established the national quality control index, monitoring network and improvement platform for cerebrovascular disease medical treatment. More than 200 SCI papers have been published attributing to as the first ranks in the number of Elsevier Scopus database (the topic of ischemic stroke and transient ischemic attack)and the total cited times in the last five years. As the first accomplice, he won the award of second prize of National Science and Technology Progress, two of first prizes of provincial and ministerial level, and one of the first national Innovation MEDALS.